Background: Magnetic resonance imaging of the prostate is a major diagnostic tool in prostate cancer detection. In 2012, prostate imaging reporting and data system (PI-RADS) was published by the European society of urogenital radiology. Due to certain limitations in this version, a revised version named Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) was proposed by the American College of Radiology in 2014 Objectives: To evaluate the role of multiparametric magnetic resonance imaging based prostate imaging reporting and data system (PI-RADS) version 2 for the assessment of peripheral zone prostate cancer and its correlation with the T staging, prostatic specific antigen (PSA) levels and apparent diffusion coefficient (ADC) values. Patients and Methods: Eighty seven patients underwent MRI at 1.5 T units. Dynamic contrast enhanced (DCE) imaging was done in 73 patients
Background
Detection of prostate cancer is a big challenge. MRI helps in localizing prostate cancer with further guidance in the biopsy (1) . Due to the high incidence of the disease, parameters for detection of early prostate cancer are controversial (2) . In May 2010 Ad MeTech foundation's international prostate MRI working group suggested the use of prostate imaging reporting and assessment system just like breast imaging-reporting and data system (BI-RADS) for breast cancer (3) . The European society of urogenital Radiology published the prostate imaging reporting and data system (PI-RADS) for diagnosing prostate cancer in 2012 with multiparametric magnetic resonance imaging. PI-RADS v2 is the most recently advised guideline for prostate cancer interpretation (4).
Objectives
To evaluate the role of multiparametric magnetic resonance imaging based prostate imaging reporting and data system (PI-RADS) version 2 for the assessment of peripheral zone prostate cancer and its correlation with the T Staging, prostatic-specific antigen (PSA) levels and apparent diffusion coefficient (ADC) values.
Patients and Methods

Patients
Eighty seven patients were included in the study with clinical suspicion of prostate cancer. Patients with serum PSA levels lower than 4 ng/mL or those with any contraindications to MRI were not included in the study. The location, size and morphologic features of lesions were assessed on conventional and diffusion weighted sequences. Contrast 
MRI Examination
Patients underwent MRI examinations on Philips Gyroscan Achieva 1.5 Tesla MRI and Siemens 1.5 Tesla MRI using sense body coil. Turbo spin-echo (TSE) T2-weighted (T2W) sequence was done in axial, coronal and sagittal planes us-2
Iran J Radiol. 2018; 15(1):e14038. T2-weighted image (T2WI) (A) sequence in axial section reveals uniformly hyper intensity of the peripheral zone of the prostate with no hyper intense signal on diffusion weighted images (B) or hypo intensity on apparent difusion coefficient (ADC) maps (C) giving prostate imaging reporting and dating system (PI-RADS) v2 score of 1 on both T2WI and diffusion weighted imaging (DWI). D shows a wedge shaped faint hypo intensity on T2WI in the peripheral zone in the central and right paracentral location (arrows) with no hyper intense signal on DWI (E) or hypo intensity on ADC maps (F). It was falling under the score of 2 on T2WI and 1 on DWI. As it is located in the peripheral zone, a DWI score of 1 was given finally. Patient had a serum prostate-specific antigen (S.PSA) level of 6.5 ng/mL and underwent biopsy on urologist's request and with his own consent which was negative for malignancy. T2WI (G) sequence in axial section in another patient reveals a small non-circumscribed indistinct hypo intensity in the peripheral zone of prostate on the left side (arrow), appearing isointense on DWI (H ) with hypointense signal on ADC maps (I) giving PI-RADS v2 score of 3 on T2WI and 3 on DWI . Lesion appears isointense to mildly hyper intense on pre-contrast volumetric interpolated breath-hold examination (VIBE) sequences (arrow in J) and showing early enhancement (K) and early wash out (L) on post contrast sequences-suggestive of positive pattern of enhancement on dynamic contrast enhanced (DCE). The PI-RADS v2 score of the lesion was upgraded from 3 to 4 by adding positive contrast enhancement pattern on DCE. Patient had S. PSA level of 43 ng/mL and biopsy revealed adenocarcioma. Lowest ADC value in the lesion was 0.73mm 2 /s and it was stage T2. ms, TE of 2.4 ms and NSA of 1.10 mL of intravenous contrast (Omniscan) was used. Precontrast images were obtained followed by four postcontrast dynamic sequences.
Imaging Analysis
MRI images were reviewed independently by two radiologists. The lesions confined to the peripheral zone with or without extra prostatic extensions were noted. Three ADC values of the lesion were noted and the lowest value was recorded by one radiologist. The size of the lesion was obtained in all three dimensions and the largest value was considered. Patterns of enhancement were observed on dynamic contrast enhanced (DCE) sequences. PI-RADS v2 scoring was noted by the second radiologist (Table 1 and Figure 1 ). T staging was done by both radiologists. As radical prostatectomy was not performed in our patients, T staging was carried out based on MRI findings. Both the radiologists were blind about each other's findings and the 4
Iran J Radiol. 2018; 15(1):e14038. Abbrviations: ADC, apparent diffusion coefficient; DWI, diffusion weighted imaging; PI-RADS V2, prostate imaging reporting and data system version 2; S.PSA,serum prostate-specific antigen.
serum (S) PSA levels of the patients. Biopsy report was used as gold standard.
Statistical Analysis
Statistical analysis was carried out using statistical package for social sciences (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp).
Results
Eighty seven patients were included in the study. The mean age was 70.3 ± 10.8 years (mean ± standard deviation [SD]). The mean S.PSA levels were 107.06 ± 7.97 ng/mL (mean ± standard error [SE]).
A wedge shaped hypo intensity on T2-weighted image (T2WI) in the peripheral zone in the central and right paracentral location with no hyper intense signal on DWI was seen in one patient with S.PSA level of 6.5 ng/mL. It was falling under the score of 2 on T2WI and 1 on DWI ( Figure  1) . DCE was not done due to deranged renal functions. Although it was located in the peripheral zone and PI-RADS v2 score of 1 was given finally, the patient underwent biopsy on a urologist's request and with his own consent. It was negative for malignancy. This further enhances the role of PI-RADS v2 score on DWI in peripheral zone lesions.
Two other patients with S.PSA levels of 4 -10 ng/mL had PI-RADS v2 score on T2WI and DWI of 1. The raised S.PSA levels were probably due to a previous episode of prostatitis. Repeated S.PSA levels after a one-month interval were norIran J Radiol. 2018; 15(1):e14038. 5 mal. No biopsy was done.
One patient showed a small wedge-shaped faint hypointensity in the left peripheral zone on T2WI with restriction on ADC and a wash in wash out pattern of enhancement. The PI-RADS v2 score was upgraded from 3 to 4 based on DCE findings (Figure 1 ). We included patients with a le-sion confined to the peripheral zone with or without ex-tra prostatic extensions. We statistically correlated PI-RADS v2 score with S. PSA levels, T staging and ADC values with highly significant correlation and P value < 0.005 (Tables 2 and 3 ).
Discussion
Prostate cancer is the commonest male malignancy with < 10% mortality rate. With clinical and/or biochemical suspicion, MRI helps in cancer detection and localization. To increase the accuracy, T2WI was combined with DCE, DWI, and MR spectroscopy (5, 6). Villeirs et al. concluded that a combination of MRI and MRS yields better results than either modality alone (7). Afifi et al . concluded that the combination of PI-RADS scoring and mpMRI have a promising role in detection of prostate cancer rather than using single parameter (8) .
ADC values in our study showed a highly significant statistical correlation with PI-RADS v2 scoring. With an increasing score, the mean ADC values decreased. Similar results were shown by Somford et al. (9) .
The European society of urogenital radiology published the PI-RADS for prostate cancer (PC) in 2012. Hamoen et al. reviewed the diagnostic accuracy of PI-RADS for prostate cancer detection and concluded that it is helpful in the detection of prostate cancer (10) .
In PI-RADS v1, DCE and MR spectroscopy (MRS) were also included in the protocols. But a study performed by Platzek et al. concluded that addition of these sequences do not have any added advantage (11, 12) . Rosenkrantz et al. concluded that PI-RADS v2 is an improved scoring system and will definitely help the uro-radiologists (13). Tewes et al. compared PI-RRADS versions 1 and 2 in their study and concluded that PI-RADS v2 could be more practicable clinically for malignant lesion and as is less time consuming (14) .
The dominant sequence in the peripheral zone is DWI. For transition zone lesions, T2W sequences are dominant with a supportive role of DWI and ADC maps (4). PI-RADS v2 is not used for overall staging of prostate cancer, but in our study we did locoregional staging and correlated T staging with the scores (Figure 2 ). We concluded that there was a highly significant correlation of ADC values with T2W and DWI scores with P value < 0.005 (Table 2) .
PI-RADS v2 uses a 5-point assessment scale. A 5-point scoring is used for T2W and DWI with, a 2-point scale (positive or negative) for DCE. DCE is helpful only in the indeterminate category 3 peripheral zone (PZ) lesions (15, 16) . In our study, we used DWI score as the final score. In one case, DCE score upgraded the lesion score from 3 to 4.
PI-RADS v2 assessment categories are defined with the following scores:
1: Very low (clinically significant prostatic cancer (PCa) is highly unlikely to be present).
2: Low (clinically significant PCa is unlikely to be present) 6 Iran J Radiol. 2018; 15(1):e14038.
3: Intermediate (the presence of clinically PCa disease is equivocal) 4: High (clinically significant PCa is likely to be present) 5: Very high (clinically significant PCa is highly likely to be present)
In conclusion, the dominant MR imaging sequence for the peripheral zone prostate cancer is diffusion weighted sequence and the corresponding ADC values with the role of DCE sequences in doubtful cases only. PI-RADS v2 should be routinely incorporated in the reporting protocol. Our study concluded that there is a highly significant correlation between lesion score on PI-RADS v2 with the T stage, corresponding ADC values and S.PSA levels, although larger study groups may be required for further evaluation and beyond doubt PI-RADS version 3 is already in its earliest stages.
